GlassScriptPhysician profile
Mark M Whelan
NPI 1932180460
$4,102.90
in general payments reported to CMS, 2019-2025
20 companies · $390 in 2025
The $390 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,399 · 2022: $1,304 · 2023: $574 · 2024: $436 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,399.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $825.42 | 2021-2023 | Onyx Frontier |
| Novo Nordisk INC | $553.29 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $488.17 | 2021-2023 | Xarelto |
| Irhythm Technologies, INC. | $315.25 | 2021-2022 | |
| Inspire Medical Systems, INC. | $302.62 | 2024-2025 | Inspire |
| Merck Sharp & Dohme LLC | $292.33 | 2021-2023 | Verquvo |
| Impulse Dynamics (USA) INC. | $287.34 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $238.31 | 2021-2023 | |
| Alnylam Pharmaceuticals INC. | $143.12 | 2023-2025 | Amvuttra |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $124.96 | 2022 | |
| Boston Scientific Corporation | $115.17 | 2025 | General - Therapies |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $104.93 | 2023-2024 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.34 | 2023-2024 | Jardiance |
| Heartflow, INC. | $34.12 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $28.36 | 2025 | Opsumit, Uptravi |
| Bridgebio Pharma, INC. | $27.78 | 2025 | Attruby |
| Amarin Pharma, INC. | $18.98 | 2021 | |
| Genzyme Corporation | $18.65 | 2025 | |
| Abbott Laboratories | $14.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Whelan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.